Literature DB >> 32672601

Predictors of Success in Selective Laser Trabeculoplasty.

Brandon Kuley1, Cindy X Zheng1, Qiang Ed Zhang2, Rose A Hamershock2, Michael M Lin1, Stephen J Moster1, James Murphy1, Marlene R Moster1, Courtland Schmidt1, Daniel Lee1, Michael J Pro3.   

Abstract

PURPOSE: Selective laser trabeculoplasty (SLT) is a common procedure to lower intraocular pressure (IOP) in patients with glaucoma. However, reports are conflicting regarding what factors contribute to SLT success. The purpose of this study was to determine predictors of SLT success.
DESIGN: Retrospective case series. PARTICIPANTS: All patients treated with SLT between January 1, 2012, and June 30, 2018.
METHODS: Baseline, demographic, procedural, and ophthalmic examination data were recorded at the time of first SLT treatment. Intraocular pressure and medication data were recorded at all follow-up visits. MAIN OUTCOME MEASURES: Selective laser trabeculoplasty success was defined as IOP decrease of 20% or more from baseline at the 3-month, 6-month, and 12-month follow-up visits. Eyes were considered to have failed and were censored when additional SLT or glaucoma surgery was performed. Patients were excluded if they had less than 3 months of follow-up.
RESULTS: A total of 997 eyes from 677 patients were included in the study. Mean age was 70.2±11.5 years. Selective laser trabeculoplasty success was achieved in 227 eyes (22.8%), whereas 770 eyes (77.2%) did not meet success criteria. Intraocular pressure before SLT was 21.9±5.2 mmHg while taking 2.0±1.2 medications in eyes with successful SLT, compared with 19.0±5.0 mmHg (P < 0.0001) while taking 2.1±1.3 medications (P = 0.52) in eyes with SLT failure. At the 1-year follow-up, mean IOP in eyes with SLT success was 14.7±3.2 mmHg with 2.0±1.2 medications, compared with 16.3±4.7 mmHg (P = 0.008) with a mean of 1.9±1.3 medications (P = 0.37) in eyes with SLT failure. Eyes with SLT success more often showed greater angle pigment (P = 0.03). Age, glaucoma severity, total SLT power, type of glaucoma, severity of glaucoma, visual field mean defect, and retinal nerve fiber layer thickness were not found to correlate with success. No difference was found between the rate of success based on treatments before SLT, whether surgical or medical.
CONCLUSIONS: In this large cohort of eyes undergoing SLT, greater IOP and angle pigment before SLT correlated positively with SLT success. Age, total SLT power, severity of glaucoma, and prior treatments were not associated with SLT success or failure.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 32672601     DOI: 10.1016/j.ogla.2019.11.010

Source DB:  PubMed          Journal:  Ophthalmol Glaucoma        ISSN: 2589-4196


  4 in total

Review 1.  A Review of Selective Laser Trabeculoplasty: "The Hype Is Real".

Authors:  Tomislav Sarenac; Anela Bečić Turkanović; Peter Ferme; Tomaž Gračner
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

2.  Real-world data from selective laser trabeculoplasty in Brazil.

Authors:  Ricardo Y Abe; Heloísa A Maestrini; Guilherme B Guedes; Marcelo M Nascimento; Camila I Iguma; Hérika Danielle de Miranda Santos; Muna Georges Nasr; Ricarte P Lucena-Junior; Tiago S Prata
Journal:  Sci Rep       Date:  2022-02-04       Impact factor: 4.379

3.  Intraocular Pressure-Lowering Efficacy of a Sustained-Release Bimatoprost Implant in Dog Eyes Pretreated with Selective Laser Trabeculoplasty.

Authors:  Corine Ghosn; Lakshmi Rajagopalan; Sveti Ugarte; Shruti Mistry; Werhner Orilla; Margot L Goodkin; Michael R Robinson; Michael Engles; Mohammed Dibas
Journal:  J Ocul Pharmacol Ther       Date:  2022-04-18       Impact factor: 2.850

Review 4.  Energy Dose-Response in Selective Laser Trabeculoplasty: A Review.

Authors:  Nathan Radcliffe; Gus Gazzard; Thomas Samuelson; Peng Khaw; Xinghuai Sun; Tin Aung; Dennis Lam; Kuldev Singh; L Jay Katz; Michael Aronov; Zachary Sacks; Yoram Solberg; Richard Lindstrom; Michael Belkin
Journal:  J Glaucoma       Date:  2022-06-15       Impact factor: 2.290

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.